Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review

Frontiers in Medicine

Medicine

Yuling Shi¹  Luyang Kong¹  Yuexin Zhang¹  Jiajing Lu¹  Dawei Huang¹  Xuemei Yi¹  Ying Li¹ 

[1] Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China;Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China;

关键词: ustekinumab;    bullous pemphigoid;    psoriasis;    case report;    treatment;   

DOI  :  10.3389/fmed.2023.1171802

 received in 2023-02-22, accepted in 2023-03-29,  发布年份 2023

来源: Frontiers

【 摘 要 】

Ustekinumab is a biological therapy that has been approved for treating moderate-to-severe psoriasis. Although injection site reactions, nasopharyngitis, headaches, and infections are the common adverse events associated with ustekinumab, the development of bullous pemphigoid (BP) is also thought to be related to ustekinumab. Given that psoriasis itself can be complicated by BP, it is worthwhile to investigate the relationship between ustekinumab, psoriasis, and BP. Here we report a case of a male patient who developed BP twice after psoriasis treatment with ustekinumab. The patient’s psoriasis and BP were brought under control by discontinuing ustekinumab and administering methotrexate, minocycline, and topical corticosteroids. Because of the increasing use of biologics in patients with psoriasis, BP should be considered a potential adverse event associated with ustekinumab.

【 授权许可】

Unknown   
Copyright © 2023 Kong, Huang, Lu, Zhang, Li, Yi and Shi.